SCHEMBL71274

SCHEMBL71274

OCCC1CN(C(c2ccccc2)c2ccccc2)C1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 1/20 0.43
OPRM1 P35372 5/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
OPRD1 P41143 2/20 0.42
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
CHRM5 P08912 1/20 0.42
ADRA2A P08913 1/20 0.42
ADORA3 P0DMS8 1/20 0.42
CYP2D6 P10635 1/20 0.42
CHRM1 P11229 1/20 0.42
CHRM3 P20309 1/20 0.42
DRD1 P21728 1/20 0.42
ADRA1D P25100 1/20 0.42
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42
HRH1 P35367 1/20 0.42
DRD3 P35462 1/20 0.42
HTR2B P41595 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5283241 0.88 DPP4 (0.41) SLC6A9OPRM1MEN1KMT2AOPRD1
SCHEMBL72670 0.85 MEN1 (0.48) SLC6A9OPRM1MEN1KMT2AOPRD1
Hydrochloric Acid SCHEMBL3552812 0.84 MEN1 (0.47) SLC6A9OPRM1MEN1KMT2AOPRD1
SCHEMBL8473380 0.83 L3MBTL3 (0.53) OPRM1MEN1KMT2AOPRD1CHRM2
SCHEMBL9682612 0.83 CYP2D6 (0.52) OPRM1KMT2AOPRD1CHRM2CYP2D6
SCHEMBL5969007 0.82 HRH1 (0.44) SLC6A9OPRM1MEN1KMT2AOPRD1
SCHEMBL14491539 0.82 DPP4 (0.50) SLC6A9OPRM1MEN1KMT2AOPRD1
SCHEMBL16759363 0.79 SLC6A9 (0.46) SLC6A9OPRM1MEN1KMT2AOPRD1
SCHEMBL5278935 0.79 DPP4 (0.42) SLC6A9OPRM1MEN1KMT2AOPRD1
SCHEMBL13596965 0.79 DPP4 (0.58) SLC6A9OPRM1MEN1KMT2AOPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1961750-B1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO CO LTD (JP) 2013-09-18 EP disclosed
US-20130065882-A1 VLA-4 inhibitory drug MACHINAGA NOBUO (JP) 2013-03-14 US disclosed
US-20130065882-A1 VLA-4 inhibitory drug MACHINAGA NOBUO (JP) 2013-03-14 US disclosed
US-20130065882-A1 VLA-4 inhibitory drug MACHINAGA NOBUO (JP) 2013-03-14 US disclosed
US-20120157437-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-06-21 US disclosed
US-20120157437-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-06-21 US disclosed
US-20120157437-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-06-21 US disclosed
US-8129366-B2 VLA-4 inhibitory drug DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-06 US disclosed
US-8129366-B2 VLA-4 inhibitory drug DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-06 US disclosed
US-8129366-B2 VLA-4 inhibitory drug DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-06 US disclosed
US-20090233901-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed
US-20090233901-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed
US-20090233901-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed
EP-1961750-A1 VLA-4 INHIBITORY DRUG Daiichi Sankyo Company, Limited (JP) 2008-08-27 EP disclosed
US-20050096297-A1 Antibacterial agents ELLSWORTH EDMUND L (US) 2005-05-05 US disclosed
US-20050096308-A1 Antibacterial agents ELLSWORTH EDMUND L (US) 2005-05-05 US disclosed
WO-2005026146-A1 AZETIDINYL QUINOLONES AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY LLC (US) 2005-03-24 WO disclosed
WO-2005026153-A1 QUINAZOLINE-2, 4-DIONES AS ANTIBACTERIAL AGENTS WARNER-LAMBERT COMPANY LLC (US) 2005-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157437-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 SLC6A9 1852/4885OPRM1 383/4885MEN1 4254/4885
US-20130065882-A1 VLA-4 inhibitory drug VCAM1, ITGB4, ITGA4 SLC6A9 1870/4885OPRM1 376/4885MEN1 4337/4885
US-20050096297-A1 Antibacterial agents MRPL21, RPN2, FBL SLC6A9 3735/4885OPRM1 1670/4885MEN1 2732/4885
US-20090233901-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 SLC6A9 1230/4885OPRM1 844/4885MEN1 4226/4885
US-20050096308-A1 Antibacterial agents MRPL21, RPN2, FBL SLC6A9 3735/4885OPRM1 1670/4885MEN1 2732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.